Microbicides

  • The Ring Study

    This page on the website of the International Partnership for Microbicides (IPM) provides information and links to resources about The Ring Study, a clinical trial designed to determine whether a monthly vaginal ring that delivers the antiretroviral drug dapivirine helps prevent HIV infection in women and is safe for long-term use. The Ring Study, which enrolled 1,959 women at six sites in South Africa and one site in Uganda, was one of two trials of the dapivirine ring to demonstrate a protective effect against HIV.

  • ASPIRE – MTN 020

    Links are provided to information about ASPIRE (A Study to Prevent Infection with a Ring for Extended Use), a Phase III safety and effectiveness trial of a vaginal ring containing the antiretroviral drug dapivirine that enrolled 2,629 women at several sites in Africa and was one of two trials of this monthly ring to demonstrate a protective effect against HIV infection.

  • Preparing for the Delivery of Microbicides: Lessons from the Implementation of Integrated Reproductive Health and HIV Services

    This brief summarizes the results of a mixed methods study in Kenya that measured the extent to which integrated services are delivered to targeted beneficiaries in public-sector health facilities as intended and identified the health systems-level factors that facilitate and impede effective delivery of integrated reproductive health and HIV services.

  • Microbicides Readiness Assessment Tool

    FHI 360 designed this tool to help managers in public health facilities evaluate the extent to which a facility has the material, technical, and human resources necessary to provide microbicides.

  • Shaping the Operations Research Agenda for Antiretroviral-Based Prevention Products for Women: Gels and Rings

    In 2012 the Population Council organized a consultation on an operations research agenda as part of a larger initiative, funded by the US Agency for International Development, to prepare for microbicide introduction. The consultation report outlines the ideas the 40 participants generated for priority research topics and approaches.

  • Tenofovir Gel for HIV Prevention for Women: Perspectives of Key Opinion Leaders from India

    This abstract of an article published in Health Policy and Technology presents key opinion leaders' perspectives from India on the introduction of tenofovir vaginal gel for HIV prevention among women. Overall, respondents were supportive but expressed caveats about the role tenofovir gel might play in the overall HIV-prevention program.

  • Policy And Programme Considerations For ARV-Based Prevention For Women: Insights From Key Opinion Leaders In Zimbabwe About Tenofovir Gel

    This report describes the process and outcomes of a systematic inquiry among key opinion leaders in Zimbabwe about program and policy considerations to address in preparation for the potential introduction of tenofovir gel. Most respondents were supportive of introducing tenofovir gel should it prove effective, with several caveats, and safety and efficacy were the chief concerns of all respondents.

  • Setting the Stage for ARV-Based Prevention for Women: A Snapshot of the Zimbabwean Context

    A program brief summarizes the findings of a landscape analysis conducted in Zimbabwe as part of a process developed by the Population Council to help policymakers and program managers identify the most strategic opportunities for introducing tenofovir gel. Based on a desk review and interviews with key decision makers, the brief reviews the epidemiologic context of the HIV epidemic, highlights policies and programs related to HIV, and provides other information relevant to potential introduction of tenofovir vaginal gel in Zimbabwe.

  • Program and Policy Considerations for Tenofovir Gel in India

    A program brief summarizes the findings of a landscape analysis conducted in India as part of a process developed by the Population Council to help policymakers and program managers identify the most strategic opportunities for introducing tenofovir gel. Based on a desk review and interviews with key decision makers, the brief reviews the epidemiologic context of the HIV epidemic, highlights policies and programs related to HIV, and provides other information relevant to potential introduction of tenofovir vaginal gel in India.

  • Assessing Physical Delivery of PrEP in Support of Proof of Deliverability: Results from South Africa

    The findings from an assessment of the feasibility and potential impact of delivering antiretroviral (ARV)-based oral and injectable pre-exposure prophylaxis (PrEP) and vaginal microbicide gels in South Africa are summarized in this brief.

Pages